Severity of craniosynostosis in humans varies widely even in patients with identical genetic 17 mutations. In this study we compared RNA sequencing data from cranial tissues of a severe 18 form of Crouzon craniosynostosis syndrome (C57BL/6 FGFR2 C342Y/+ mice) with those of a less 19 severe form of Crouzon craniosynostosis (BALB/c FGFR2 C342Y/+ mice) to identify genetic 20 modifiers that influence craniosynostosis phenotype severity. Comparison of the mice revealed 21 neonatal onset of coronal suture fusion in the form of suture obliteration in C57BL/6 mice (88% 22 incidence, p<.001 between genotypes). Coronal suture fusion in the form of point fusions across 23 the suture occurred at approximately 4 weeks after birth, with less severe skull shape 24 abnormalities, in BALB/c mice. Substantially fewer genes were differentially expressed in 25 BALB/c FGFR2 +/+ vs. FGFR2C 342Y/+ mice (87 out of 15,893 expressed genes) than C57BL/6 26 FGFR2C +/+ vs. FGFR2C 342Y/+ mice (2,043 out of 19,097 expressed genes). Further investigation 27 revealed differential expression of coronal suture fusion associated genes, eph/ephrin boundary 28 genes, cell proliferation genes, osteoblast differentiation genes and epigenetic regulators, 29 among others. The most striking pattern in the data was the minimal change in gene expression 30 seen for most genes in BALB/c FGFR2 +/+ vs. FGFR2C 342Y/+ mice. Analysis of protein processing 31 and lysosomal components support the hypothesis that the craniosynostosis phenotype is less 32 severe in BALB/c mice because the mutant FGFR2C 342Y protein is not expressed to the same 33 extent as that seen in C57BL/6 mice. Together, these results suggest that a strategy aimed at 34 increasing degradation of the mutant receptor or downstream signaling inhibition could lead to 35 diminished phenotype severity. 36 37 38 40 41 Abbreviations: FGFR, Fibroblast Growth Factor Receptor; Msx1, Msh homeobox 1; 42 Msx2, Msh homeobox 2; Twist1, Twist-related protein 1; Zic1, Zinc finger of the cerebellum 1; 43 En1, Homeobox protein engrailed-1; Ezh2, Enhancer of zeste homolog 2; Mgat5b, Alpha-1,6-44 mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B; Mgat5, Alpha-1,6-45 mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A; Hspa1b, Heat shock 70kDa 46 protein 1B; Hspa1a, Heat shock 70 kDa protein 1; Hspa2, Heat shock-related 70 kDa protein 2; 47 Clgn, Calmegin; Hspb1, Heat shock protein 27; Hexa, Hexosaminidase A; Hexb, 48 Hexosaminidase B; Mpo, Myeloperoxidase; Prtn2, Proline-rich transmembrane protein 49 2; Prss57, Serine Protease 57; Uchl1, Ubiquitin carboxy-terminal hydrolase L1; Mik67, 50 Proliferation-Related Ki-67 Antigen; Ccnb1, Cyclin B1; Aurkb, Aurora kinase 51 B; Cdk1, Cyclin-dependent kinase 1; Ccnb2, Cyclin B2 : Gata1, GATA-binding factor 1; E2F2, 52 E2F Transcription Factor 2; Spp1, Osteopontin; Bglap, Bone gamma-carboxyglutamic acid-53 containing protein; Runx2, Runt-related transcription factor 2; Sp7, Osterix; Alpl, Tissue-54 nonspecific alkaline phosphatase; Padi2, Protein-arginine deiminase type-2; Efn, Ephrin; Eph, 55 Eph receptor.
at -80C until use. 156 157 RNA sequencing 158 RNA sequencing was performed as previously reported (Paradise et al., 2019) . Expression 159 values for each gene were normalized to one million reads and corrected for gene length (reads 160 per kilobase per million mapped reads, RPKM). RPKM values were determined for each 161 genotype and strain group using thee independent biologic replicates.
162
Quality of the raw reads data for each sample was checked using FastQC version v0.11.3.
163
We used default parameter settings for alignment, with the exception of: "--b2-very-sensitive"
164
telling the software to spend extra time searching for valid alignments. We used FastQC for a 165 second round of quality control (post-alignment), to ensure that only high quality data would be 166 input to expression quantitation and differential expression analysis. We used HTSeq version 167 0.6.1/DESeq2 version 1.14.1 (Zhang et al., 2014), using UCSC mm10.fa as the reference 168 genome sequence (Kent WJ, 2002 ) .
169
We identified genes and transcripts as being differentially expressed based on three criteria: 170 test status = "OK", FDR ≤ 0.05, and fold change ≥ ± 1.5. Expression quantitation was performed 171 with HTSeq version 1.14.1, to count non-ambiguously mapped reads only. Data were pre-172 filtered to remove genes with 0 counts in all samples. Normalization and differential expression 173 were performed with DESeq2 using a negative binomial generalized linear model. Principal 174 component analysis and non-normalized distribution plots indicated good quality data consistent 175 with the set of differentially expressed genes. Samples did not appear to strongly cluster by 176 background genotype which were divided between batches. Therefore, batch effect is unlikely to 177 have a large impact.
178
The data was analyzed using Advaita Bio's iPathway software 179 (https://www.advaitabio.com/ipathwayguide), which implements the 'Impact Analysis' approach, as described in (Draghici, 2007 , Tarca, 2008 , Donato, 2013 , Ahsan 2018 ." The dataset is 181 available at the Gene Expression Omnibus, accession number GSE143628. Comparisons 182 between groups (three independent biologic replicates per group) were made using post hoc 
200
Craniofacial Shape
201
Representative isosurface micro CT images of skulls demonstrate that Crouzon mice 202 carrying the FGFR2 +/C342Y mutation differ in morphology from their wild type counterparts, and 203 that the shape differences between mutant and wild type are more apparent in mice on the 204 C57BL/6 than the BALB/c background ( Fig. 1) . C57BL/6 FGFR2 +/C342Y skulls are tall, dome 205 shaped and exhibit midface hypoplasia that is more severe than that seen in BALB/c FGFR2 +/C342Y mice. Craniofacial skeletal linear measurements normalized to total skull length 207 confirmed the consistencies of the above observations and revealed many differences between 208 FGFR2 342Y/+ Crouzon and FGFR2 +/+ wild type mice in terms of skull shape on both congenic 209 backgrounds (Fig. 2) . Between the two strains, C57BL/6 FGFR2 342Y/+ Crouzon mice had greater 210 changes in skull width, nose length and inner canthal distances when compared to BALB/c 211 FGFR2 342Y/+ Crouzon mice.
213

Craniosynostosis and Malocclusion
214
Analysis of craniosynostosis revealed a high incidence of coronal suture fusion in three-
215
week-old C57BL/6 FGFR2 C342Y/+ mice as compared to FGFR2 +/+ mice (88% vs. 0%, p<.001). In 216 contrast, the coronal suture was not fused in any in three-week-old BALB/c FGFR2 +/+ or 217 FGFR2 C342Y/+ mice. A class III malocclusion was evident in 86% of C57BL/6 FGFR2 C342Y/+ mice 218 and in 27% of BALB/c FGFR2 C342Y/+ (p<.03), while no malocclusion was identified in FGFR2 +/+ 219 mice on either genetic background.
221
Identification of Differentially Expressed Genes in C57BL/6 and BALB/c Cranial Bones
222
Overall gene expression analyses showed that for some individual comparisons, there are 223 over 1,000 differentially expressed genes, while other comparisons have less than 10 unique 224 differentially expressed genes that reached statistical significance ( Fig. 3) . To look for pre-225 existing modifiers of differentially expressed genes between the two genetic strains, we 
230
FGFR2 C342Y/+ tissues in C57BL/6 and BALB/c strains. Volcano plots demonstrate differential 231 gene expression between C57BL/6 and BALB/c FGFR2 +/+ tissues, and between C57BL/6 and BALB/c FGFR2 C342Y/+ tissues ( Fig. 4) . Of note, substantially fewer genes were differentially 233 expressed in BALB/c FGFR2C 342Y/+ vs. FGFR2 +/+ mice (87 out of 15,893 genes with measured 234 expression) than in C57BL/6 FGFR2C 342Y/+ vs. FGFR2 +/+ mice (2,043 out of 19,097 genes with 235 measured expression). When limiting to those genes that were only differentially expressed in We found that En1 (engrailed 1) expression was significantly diminished in C57BL/6 258 compared to BALB/c cranial tissues regardless of mutation (FGFR2 +/+ or FGFR2 342Y/+ ) ( Fig. 5 ).
259
Notably, En1 expression was not different between mutant and wild type mice on the BALB/c 260 background. In contrast, En1 was expressed to a significantly greater extent in C57BL/6 261 FGFR2 342Y/+ as compared to C57BL/6 FGFR2 +/+ cranial tissues indicating that expression of the 262 mutant receptor feeds back on En1 expression in C57BL/6 mice. En1 is a homeodomain 263 transcription factor previously shown to be essential for proper mesoderm/neural crest boundary 
273
We found that the H3K27 methyl transferase Ezh2 was significantly downregulated upon 274 expression of the FGFR2 C342Y mutation in C57BL/6 compared to BALB/c mice ( Fig. 5) . Genetic 
279
PCA analysis of epigenetic regulators also reveals segregation by genotype and strain 280 (Supplemental Figure 2) . Analysis of the RNA seq data by the GO term histone modifier genes 281 revealed thirteen histone modifying genes to be differentially expressed between the groups Table 1 ). In addition, a search for GO term nucleosome reveals numerous differences between C57BL/6 and BALB/c cranial tissues (Supplemental Table 2 ) regardless 284 of mutation (FGFR2 +/+ or FGFR2 342Y/+ ). In addition, no nucleosome genes are differentially 285 expressed in BALB/c FGFR2 +/+ compared to FGFR2 342Y/+ tissues, while six genes are 286 significantly downregulated by expression of the FGFR2 342Y mutant receptor in C57BL/6 mice.
(Supplemental
287
Together this data indicates both that the chromosome landscape is different in FGFR2 +/+ 288 C57BL/6 vs. FGFR2 +/+ BALB/c mice, and in FGFR2 342Y/+ C57BL/6 vs. FGFR2 342Y/+ BALB/c mice.
289
It should also be noted that Padi2, a histone H3-R26 citrullination enzyme known for controlling 
294
Differential Expression of Protein Modification and Degradation Genes
295
The pattern of minimal difference in gene expression between mutant and wild type mice on 296 the BALB/c background is noticeable and repeatable in the RNA seq data. This pattern in the 297 data suggested diminished expression and/or activity of the mutant FGFR2 C342Y receptor in 298 BALB/c mice, which led us next to look for changes in gene expression that could account for 299 differential receptor processing and/or degradation between the two strains. To investigate gene 300 changes that may lead to diminished mutant receptor protein expression in BALB/c as 301 compared to C57BL/6 mice, we analyzed the sequencing data for differences in genes that 302 could influence wild type and mutant FGFR2 modification and degradation (Fig. 6) . The N- Activation mutations in FGFR2IIIc cause craniosynostosis of varying severity in humans 360 and mice. As an initial step towards identifying potential genetic modifiers of the disorder, we backcrossed the FGFR2C 342Y/+ mouse model of Crouzon syndrome onto inbred background 362 strains. We found that FGFR2C 342Y/+ mice on the C57BL/6 strain exhibits earlier onset and more 363 extensive coronal suture fusion, worse skull shape abnormalities and a greater incidence of 364 malocclusion than FGFR2C 342Y/+ mice on the BALB/c strain. This data indicates increased 365 craniofacial phenotype severity on the C57BL/6 background, which is consistent with other prior 366 investigations which showed a more severe phenotype in the FGFR3 P244R mouse model of 
428
A principal component analysis of epigenetic regulators revealed that epigenetic regulator 429 genes cluster differently dependent upon genotype and background strain. Analysis of the data 430 by the GO term histone modifier genes revealed 13 genes that were differentially expressed 431 between genotypes and background strains. Analysis by the GO term nucleosome genes 432 revealed that six nucleosome genes were differentially expressed between C57BL/6 FGFR2 +/+ 433 and FGFR2 C342Y/+ cranial tissues but none were differentially expressed between BALB/c 434 FGFR2 +/+ and FGFR2 C342Y/+ cranial tissues. Multiple nucleosome genes were also differentially 435 expressed between C57BL/6 and BALB/c of mutant and wild type genotypes. This data 436 demonstrates that the epigenetic landscape is very likely different in cranial tissues of C57BL/6 437 and BALB/c mice, such that epigenetic landscape differences may predispose to a more severe Zhang, Z.H., Jhaveri, D.J., Marshall, V.M., Bauer, D.C., Edson, J., Narayanan, R.K., Robinson, G.J., 721
Lundberg, A.E., Bartlett, P.F., Wray, N.R., Zhao, Q.Y., 2014. A comparative study of 722 techniques for differential expression analysis on RNA-Seq data. PLoS One 9, e103207. 
